123 related articles for article (PubMed ID: 24988121)
1. Traumatic brain injury-related attention deficits: treatment outcomes with lisdexamfetamine dimesylate (Vyvanse).
Tramontana MG; Cowan RL; Zald D; Prokop JW; Guillamondegui O
Brain Inj; 2014; 28(11):1461-72. PubMed ID: 24988121
[TBL] [Abstract][Full Text] [Related]
2. Lisdexamfetamine dimesylate in adults with attention-deficit/ hyperactivity disorder who report clinically significant impairment in executive function: results from a randomized, double-blind, placebo-controlled study.
Adler LA; Dirks B; Deas PF; Raychaudhuri A; Dauphin MR; Lasser RA; Weisler RH
J Clin Psychiatry; 2013 Jul; 74(7):694-702. PubMed ID: 23945447
[TBL] [Abstract][Full Text] [Related]
3. Short-term effects of lisdexamfetamine dimesylate on cardiovascular parameters in a 4-week clinical trial in adults with attention-deficit/hyperactivity disorder.
Adler LA; Weisler RH; Goodman DW; Hamdani M; Niebler GE
J Clin Psychiatry; 2009 Dec; 70(12):1652-61. PubMed ID: 20141706
[TBL] [Abstract][Full Text] [Related]
4. Double-blind, placebo-controlled, crossover study of the efficacy and safety of lisdexamfetamine dimesylate in college students with ADHD.
Dupaul GJ; Weyandt LL; Rossi JS; Vilardo BA; O'Dell SM; Carson KM; Verdi G; Swentosky A
J Atten Disord; 2012 Apr; 16(3):202-20. PubMed ID: 22166471
[TBL] [Abstract][Full Text] [Related]
5. Effects of open-label lisdexamfetamine dimesylate on self-reported quality of life in adults with ADHD.
Brams M; Giblin J; Gasior M; Gao J; Wigal T
Postgrad Med; 2011 May; 123(3):99-108. PubMed ID: 21566420
[TBL] [Abstract][Full Text] [Related]
6. Maintenance of efficacy of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder: randomized withdrawal design.
Brams M; Weisler R; Findling RL; Gasior M; Hamdani M; Ferreira-Cornwell MC; Squires L
J Clin Psychiatry; 2012 Jul; 73(7):977-83. PubMed ID: 22780921
[TBL] [Abstract][Full Text] [Related]
7. Atomoxetine for attention deficits following traumatic brain injury: results from a randomized controlled trial.
Ripley DL; Morey CE; Gerber D; Harrison-Felix C; Brenner LA; Pretz CR; Cusick C; Wesnes K
Brain Inj; 2014; 28(12):1514-22. PubMed ID: 25180876
[TBL] [Abstract][Full Text] [Related]
8. European, randomized, phase 3 study of lisdexamfetamine dimesylate in children and adolescents with attention-deficit/hyperactivity disorder.
Coghill D; Banaschewski T; Lecendreux M; Soutullo C; Johnson M; Zuddas A; Anderson C; Civil R; Higgins N; Lyne A; Squires L
Eur Neuropsychopharmacol; 2013 Oct; 23(10):1208-18. PubMed ID: 23332456
[TBL] [Abstract][Full Text] [Related]
9. Aggregated n-of-1 trials of central nervous system stimulants versus placebo for paediatric traumatic brain injury--a pilot study.
Nikles CJ; McKinlay L; Mitchell GK; Carmont SA; Senior HE; Waugh MC; Epps A; Schluter PJ; Lloyd OT
Trials; 2014 Feb; 15():54. PubMed ID: 24524676
[TBL] [Abstract][Full Text] [Related]
10. Effect size of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder.
Wigal T; Brams M; Gasior M; Gao J; Giblin J
Postgrad Med; 2011 Mar; 123(2):169-76. PubMed ID: 21474905
[TBL] [Abstract][Full Text] [Related]
11. Open-label administration of lisdexamfetamine dimesylate improves executive function impairments and symptoms of attention-deficit/hyperactivity disorder in adults.
Brown TE; Brams M; Gao J; Gasior M; Childress A
Postgrad Med; 2010 Sep; 122(5):7-17. PubMed ID: 20861583
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of lisdexamfetamine dimesylate in adolescents with attention-deficit/hyperactivity disorder.
Findling RL; Childress AC; Cutler AJ; Gasior M; Hamdani M; Ferreira-Cornwell MC; Squires L
J Am Acad Child Adolesc Psychiatry; 2011 Apr; 50(4):395-405. PubMed ID: 21421179
[TBL] [Abstract][Full Text] [Related]
13. Traumatic Brain Injury-Related Attention Deficits in Children: A Controlled Treatment Trial with Lisdexamfetamine Dimesylate (Vyvanse).
Tramontana MG; Prokop JW; Williamson E; Duffie T; LaFever H
Brain Sci; 2021 Jan; 11(1):. PubMed ID: 33467178
[TBL] [Abstract][Full Text] [Related]
14. Prediction of placebo response in 2 clinical trials of lisdexamfetamine dimesylate for the treatment of ADHD.
Waxmonsky JG; Waschbusch DA; Glatt SJ; Faraone SV
J Clin Psychiatry; 2011 Oct; 72(10):1366-75. PubMed ID: 21367347
[TBL] [Abstract][Full Text] [Related]
15. Central nervous system stimulants for secondary attention deficit-hyperactivity disorder after paediatric traumatic brain injury: a rationale and protocol for single patient (n-of-1) multiple cross-over trials.
Senior HE; McKinlay L; Nikles J; Schluter PJ; Carmont SA; Waugh MC; Epps A; Lloyd O; Mitchell GK
BMC Pediatr; 2013 May; 13():89. PubMed ID: 23710976
[TBL] [Abstract][Full Text] [Related]
16. Effect of lisdexamfetamine dimesylate on parent-rated measures in children aged 6 to 12 years with attention-deficit/hyperactivity disorder: a secondary analysis.
Lopez FA; Ginsberg LD; Arnold V
Postgrad Med; 2008 Sep; 120(3):89-102. PubMed ID: 18824828
[TBL] [Abstract][Full Text] [Related]
17. Executive function deficits in children with attention-deficit/hyperactivity disorder and improvement with lisdexamfetamine dimesylate in an open-label study.
Turgay A; Ginsberg L; Sarkis E; Jain R; Adeyi B; Gao J; Dirks B; Babcock T; Scheckner B; Richards C; Lasser R; Findling RL
J Child Adolesc Psychopharmacol; 2010 Dec; 20(6):503-11. PubMed ID: 21186969
[TBL] [Abstract][Full Text] [Related]
18. The effects of lisdexamfetamine dimesylate on the driving performance of young adults with ADHD: a randomized, double-blind, placebo-controlled study using a validated driving simulator paradigm.
Biederman J; Fried R; Hammerness P; Surman C; Mehler B; Petty CR; Faraone SV; Miller C; Bourgeois M; Meller B; Godfrey KM; Reimer B
J Psychiatr Res; 2012 Apr; 46(4):484-91. PubMed ID: 22277301
[TBL] [Abstract][Full Text] [Related]
19. Clinical effects of lisdexamfetamine and mixed amphetamine salts immediate release in adult ADHD: results of a crossover design clinical trial.
Adler LA; Alperin S; Leon T; Faraone S
Postgrad Med; 2014 Sep; 126(5):17-24. PubMed ID: 25295646
[TBL] [Abstract][Full Text] [Related]
20. The efficacy and safety profile of lisdexamfetamine dimesylate, a prodrug of d-amphetamine, for the treatment of attention-deficit/hyperactivity disorder in children and adults.
Najib J
Clin Ther; 2009 Jan; 31(1):142-76. PubMed ID: 19243715
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
